

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



## Novel synthesised flavone derivatives provide significant insight into the structural features required for enhanced anti-proliferative activity

Received 00th January 20xx,  
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Divyashree Ravishankar<sup>a</sup>, Kimberly A. Watson<sup>b</sup>, Francesca Greco<sup>a†</sup>, Helen M. I. Osborn<sup>a†</sup>

With many cancers showing resistance to current chemotherapies, the search for novel anti-cancer agents is attracting considerable attention. Natural flavonoids have been identified as useful leads in such programmes. However, since an in-depth understanding of the structural requirements for optimum activity is generally lacking, further research is required before the full potential of flavonoids as anti-proliferative agents can be realised. Herein a broad library of 76 methoxy and hydroxy flavones, and their 4-thio analogues, was constructed and their structure-activity relationships for anti-proliferative activity against the breast cancer cell lines MCF-7 (ER+ve), MCF-7/DX (ER+ve, anthracycline resistant) and MDA-MB-231 (ER-ve) were probed. Within this library, 42 compounds were novel, and all compounds were afforded in good yields and > 95% purity. The most promising lead compounds, specifically the novel hydroxy 4-thioflavones 15f and 16f, were further evaluated for their anti-proliferative activities against a broader range of cancer cell lines by the National Cancer Institute (NCI), USA and displayed significant growth inhibition profiles (e.g Compound-15f: MCF-7 ( $GI_{50} = 0.18 \mu\text{M}$ ), T-47D ( $GI_{50} = 0.03 \mu\text{M}$ ) and MDA-MB-468 ( $GI_{50} = 0.47 \mu\text{M}$ ) and compound-16f: MCF-7 ( $GI_{50} = 1.46 \mu\text{M}$ ), T-47D ( $GI_{50} = 1.27 \mu\text{M}$ ) and MDA-MB-231 ( $GI_{50} = 1.81 \mu\text{M}$ ). Overall, 15f and 16f exhibited 7-46 fold greater anti-proliferative potency than the natural flavone chrysin (2d). A systematic structure-activity relationship study against the breast cancer cell lines highlighted that free hydroxyl groups and the B-ring phenyl groups were essential for enhanced anti-proliferative activities. Substitution of the 4-C=O functionality with a 4-C=S functionality, and incorporation of electron withdrawing groups at C4' of the B-ring phenyl, also enhanced activity. Molecular docking and mechanistic studies suggest that the anti-proliferative effects of flavones 15f and 16f are mediated via ER-independent cleavage of PARP and downregulation of GSK-3 $\beta$  for MCF-7 and MCF-7/DX cell lines. For the MDA-MB-231 cell line, restoration of the wild-type p53 DNA binding activity of mutant p53 tumour suppressor gene was indicated.

### Introduction

Natural products and their derivatives provide a significant number of new chemical leads for drug discovery programmes within a wide range of clinical

areas<sup>1</sup>. For example, analysis of plant-based compounds has highlighted many potential clinical applications for flavonoids<sup>2</sup>. Within the area of flavonoids as anticancer agents<sup>3-11</sup>, the success of such approaches has been exemplified through the development of flavone derivatives such as flavopiridol (for chronic lymphocytic leukemia)<sup>12,13,14</sup>, silibinin (for prostate cancer)<sup>15</sup>, and quercetin<sup>16</sup> and its derivative QC12<sup>17</sup> (for ovarian cancer), which are at various stages of clinical application. Although the natural flavonoids demonstrate anti-proliferative activities and can themselves act as useful leads, these activities have often been reported at pharmacologically non-achievable high micromolar concentrations (50-100  $\mu\text{M}$ )<sup>18-21</sup>. Therefore, medicinal chemistry strategies are essential to optimise the pharmacokinetic profiles of

<sup>a</sup>School of Pharmacy, University of Reading, Whiteknights, RG6 6AD, Berkshire, UK.

<sup>b</sup>School of Biological Sciences, Harborne Building, University of Reading, Whiteknights, RG6 6AS, Berkshire, UK.

<sup>†</sup>Corresponding authors

Helen. M. I. Osborn.

Tel: +44 (0)118 378-7338, E-mail address: h.m.i.osborn@reading.ac.uk.

\*Francesca Greco

Tel: +44 (0) 118 378-8244, E-mail address: f.greco@reading.ac.uk

Present Address

Reading School of Pharmacy, University of Reading, Whiteknights, Reading, UK, RG6 6AD.

Electronic Supporting Information (ESI) available: This includes the synthesis and characterisation of compounds 1a-f to 19a-f as well as figures summarising the anti-proliferative activities of compounds 1c-f to 5c-f against the MDA-MB-231 cell line and the anti-proliferative activities of compounds 6c-f to 11c-f against (A) MCF-7 cell line (B) MCF-7/DX cell line (C) MDA-MB-231 cell line. Dose response curves are also provided. See DOI: 10.1039/x0xx00000x

these compounds, in order to ensure that the full clinical applications for flavonoids are realised. In this study, we have proposed methylation of hydroxyls, and conversion of 4-C=O to 4-C=S, as a promising strategy to improve the activities of flavonoids, since these structural motifs could lead to flavonoids with desirable physicochemical properties such as increased lipophilicity and metabolic stability. Therefore, the aim of this study was to study the effects of methylation of free hydroxyls and 4-C=S substitution on the anti-proliferative properties of the flavonoids by undertaking the systematic design, synthesis and biological analysis of a well-defined library of hydroxy flavone analogues. In addition, synthesis of this library of compounds would also allow structure-activity relationships (SARs) to be determined. This is of particular importance for flavonoids as in-depth understanding of the SARs for anticancer properties of flavones is still limited<sup>22,23</sup>. Specifically, the significance of some of their core structural features for activity, such as hydroxyl substitutions at different positions on the flavonoid rings, and the effect of methylation of the free hydroxyls on activity, are poorly defined. Also, the impact of modifying the 4-C=O substituent on the anticancer activities of flavones has not been extensively studied.

## Results and discussion

### Design and Synthesis

To realise the aims of this study, structurally related hydroxy and methoxy flavones, and their 4-thio derivatives, were synthesised. The synthesis of the methoxy and hydroxy flavone scaffolds was achieved using a synthetic strategy involving the Baker-Venkataraman rearrangement as a key step (Scheme-1).<sup>24,25</sup> The 4-thio analogues were obtained according to Scheme-2<sup>26</sup> in 20-30% overall yield (see experimental section in supporting information material for full details).

First, the effects of methylation and 4-thio modifications on flavones with different numbers of hydroxyl groups and different positions of hydroxyls on ring-A, were investigated. Thus, 20 flavones comprising

of i) dihydroxy flavones with hydroxyl substitution on ring-A at the C-7,8 or C-5,7 positions, ii) tetrahydroxy flavones with dihydroxyl substitution on ring-A (at the C-7,8 or C-5,7 positions) and on ring-B (at the C-3' and C-4' positions), and iii) pentahydroxy flavones with dihydroxyl substitution on ring-A (at the C-5,7 position only) and on ring-B (at the C-3' and C-4' positions) as well as a hydroxyl group at the C-3 position on ring-C were designed and synthesised. The analogous methoxy and 4-thio derivatives were also prepared (compounds-**1c-f** to **5c-f**, Series-1, Figure-1).

The pentahydroxy flavone (quercetin) derivatives (**5c-f**) were obtained starting from pentahydroxy flavone (purchased) according to Scheme-3<sup>27,28</sup> in 36% overall yield and with 99% purity by HPLC. This represents an improvement on the recently reported synthesis of **5f**, both in terms of overall yield and purity<sup>29</sup> (22% overall yield and 95% purity). The panel of flavones studied herein also contained the well-known natural flavones chrysin (**2d**), luteolin (**4d**) and quercetin (**5d**) to allow comparisons to be made between the novel analogues prepared in our laboratory and some standard flavonoids. The design of further series of flavones was guided by the anti-proliferative activities of Series-1 compounds. Therefore, compound-**2f**, a dihydroxy 4-thio flavone that was identified to possess promising anti-proliferative activity in *in vitro* screening (discussed below), was considered as a candidate for further optimisation through the bioisostere approach and Topliss scheme<sup>30</sup>. This resulted in the synthesis of a focused set of dihydroxy flavone analogues (bearing C-7,8 and C-5,7 hydroxyls on ring-A) with phenyl bioisosteres (Series-2, Figure-1), and phenyl groups with electron-withdrawing substituents at the C-4' position (based on the Topliss scheme for the optimisation of phenyl ring substitution in drug design<sup>30</sup>) (Series-3, Figure-1) as ring-B. The Series-2 bioisosteric analogues of **2f** comprised of dihydroxy and dimethoxy flavones, as well as their 4-thioflavone derivatives, with a five-membered 2-thienyl and 2-furanyl group, and a six-membered 3-pyridyl group [compounds **6c-f** to **11c-f**]. Series-3 involved 7,8 and 5,7 dihydroxy, dimethoxy flavones, and their 4-thio flavone



responsive breast cancer cell lines MCF-7, and the clinically relevant anthracycline-resistant MCF-7/DX (which mimics the multi-drug resistant scenario in patients), as well as the estrogen-independent, triple negative breast cancer cell line MDA-MB-231, using the MTT assay. The initial series of compounds (Series 1, i.e. **1c-f** to **5c-f**) was first evaluated against MCF-7 and MCF-7/DX cell lines to investigate the effects of methylation and 4-thio substitution on flavones with differing numbers of hydroxyl groups as well as with different positions on the A-ring. The IC<sub>50</sub> values (half maximal inhibitory concentration) of these compounds were determined as a measure of their respective cytotoxicity and these values are tabulated in Table-1. For this series, compound-**2f** with the dihydroxy groups at the C-5,7 positions on ring-A, and 4-thio substitution, showed the highest anti-proliferative potency with IC<sub>50</sub> values of  $7.1 \pm 0.51 \mu\text{M}$  and  $34.93 \pm 5.75 \mu\text{M}$  against MCF-7 and MCF-7/DX cell lines, respectively. Compounds **1f**, **3e**, **3f**, **4d** and **5d** showed moderate cytotoxicity with IC<sub>50</sub> values of  $25.6 \pm 1.26 \mu\text{M}$ ,  $23.5 \pm 4.27 \mu\text{M}$  and  $11.8 \pm 1.79 \mu\text{M}$ , respectively however, these compounds were weakly anti-proliferative against the MCF-7/DX cell line with IC<sub>50</sub> values of  $176.3 \pm 1.61 \mu\text{M}$ ,  $>250 \mu\text{M}$  and  $>250 \mu\text{M}$ , respectively. Compounds **1c**, **1d**, **1e**, **9c**, **3c**, **3d**, **4c**, **4e**, **5c**, **5e** and **5f** were found to be less active against both MCF-7 and MCF-7/DX cell lines with IC<sub>50</sub> values  $>30 \mu\text{M}$  and  $>85 \mu\text{M}$ , respectively. The IC<sub>50</sub> values for the well-known natural flavones in this series, **2d** (chrysin), **4d** (luteolin) and **5d** (quercetin) were found to be  $25.6 \pm 1.26 \mu\text{M}$ ,  $21.6 \pm 0.81 \mu\text{M}$  and  $13.7 \pm 0.61 \mu\text{M}$ , respectively, against the MCF-7 cell line and the obtained values are in the range of their literature reported values<sup>35,36</sup>. In general, all compounds exhibited a 3-10 fold lower anti-proliferative activity against MCF-7/DX, which could be because these compounds might act as substrates of the efflux pump P-gp, which is generally over expressed in the MCF-7/DX cell line<sup>37</sup>.

Next, Series 1 compounds (**1c-f** to **5c-f**) were assessed for their anti-proliferative activities at  $10 \mu\text{M}$  concentration against an ER-ve hormone-independent breast cancer cell line, MDA-MB-231. The 4-thio

derivatives, and in particular the hydroxy compounds, exhibited greater anti-proliferative activity than the methoxy and hydroxy flavone analogues. However, no derivatives reached the IC<sub>50</sub> at  $10 \mu\text{M}$  (See supporting information, Figure-S1).

As compound-**2f** was identified as a promising lead compound, further novel analogues of compound-**2f** were prepared to discover more active flavone derivatives. Thus a series of bioisosteric analogues of the B-ring phenyl group of compound-**2f** (Series-2, compounds **6c-f** to **11c-f**), and a series of compound-**2f** analogues with electron-withdrawing substituents at the C4' position (Series-3, compounds **12c-f** to **19c-f**), along with their methoxy (both 4-C=O and 4-C=S) and their 7,8-

**Table 1.** IC<sub>50</sub> values of the compounds from Series 1 (**1c-f** to **5c-f**) against the MCF-7 and MCF-7/DX cell lines


| Chemical structure | Compound  | Substitution                     | IC <sub>50</sub> in MCF-7 | IC <sub>50</sub> in MCF-7/DX |
|--------------------|-----------|----------------------------------|---------------------------|------------------------------|
|                    | 1c        | R <sup>1,2</sup> =OMe, X=O       | 35.2 ± 4.4 μM             | 77.0 ± 4.2 μM                |
|                    | 1d        | R <sup>1,2</sup> =OH, X=O        | 38.0 ± 0.6 μM             | 86.7 ± 0.9 μM                |
|                    | 1e        | R <sup>1,2</sup> =OMe, X=S       | 34.7 ± 1.7 μM             | 90.3 ± 0.8 μM                |
|                    | 1f        | R <sup>1,2</sup> =OH, X=S        | 14.7 ± 1.0 μM             | 47.2 ± 1.2 μM                |
|                    | 2c        | R <sup>1,2</sup> =OMe, X=O       | 35.2 ± 4.4 μM             | >250 μM                      |
|                    | 2d        | R <sup>1,2</sup> =OH, X=O        | 25.6 ± 1.2 μM             | 176.3 ± 1.6 μM               |
|                    | 2e        | R <sup>1,2</sup> =OMe, X=S       | 23.5 ± 4.2 μM             | >250 μM                      |
|                    | <b>2f</b> | <b>R<sup>1,2</sup>=OH, X=S</b>   | <b>7.9 ± 0.2 μM</b>       | <b>34.9 ± 5.7 μM</b>         |
|                    | 3c        | R <sup>1,2,3,4</sup> =OMe, X=O   | >250 μM                   | >250 μM                      |
|                    | 3d        | R <sup>1,2,3,4</sup> =OH, X=O    | 97.5 ± 6.7 μM             | 183.9 ± 9.0 μM               |
|                    | 3e        | R <sup>1,2,3,4</sup> =OMe, X=S   | 11.8 ± 1.7 μM             | >250 μM                      |
|                    | 3f        | R <sup>1,2,3,4</sup> =OH, X=S    | 16.9 ± 1.2 μM             | 66.8 ± 0.7 μM                |
|                    | 4c        | R <sup>1,2,3,4</sup> =OMe, X=O   | >250 μM                   | >250 μM                      |
|                    | 4d        | R <sup>1,2,3,4</sup> =OH, X=O    | 21.6 ± 0.8 μM             | 81.1 ± 1.7 μM                |
|                    | 4e        | R <sup>1,2,3,4</sup> =OMe, X=S   | >250 μM                   | >250 μM                      |
|                    | 4f        | R <sup>1,2,3,4</sup> =OH, X=S    | 27.3 ± 1.5 μM             | 75.9 ± 3.0 μM                |
|                    | 5c        | R <sup>1,2,3,4,5</sup> =OMe, X=O | 140.0 ± 1.6 μM            | 245.1 ± 2.5 μM               |
|                    | 5d        | R <sup>1,2,3,4,5</sup> =OH, X=O  | 13.7 ± 0.6 μM             | 80.4 ± 1.7 μM                |
|                    | 5e        | R <sup>1,2,3,4,5</sup> =OMe, X=S | >250 μM                   | >250 μM                      |
|                    | 5f        | R <sup>1,2,3,4,5</sup> =OH, X=S  | 102.6 ± 5.3 μM            | 139.3 ± 6.8 μM               |

Note: Most active compound of the series is highlighted in bold.

regioisomeric analogues (both 4-C=O and 4-C=S), were synthesised and evaluated for their anti-proliferative activities. Since compound-**2f** was identified to be active below  $10 \mu\text{M}$  and  $50 \mu\text{M}$  against MCF-7 and MCF-7/DX, respectively, these subsequently synthesised compounds were initially assessed for their anti-proliferative activities at  $10 \mu\text{M}$  concentration against the MCF-7 and MDA-MB-231 cell lines, and at  $50 \mu\text{M}$  against the MCF-7/DX cell line. Compounds that reduced the cell viability below 50% in the initial screening were arbitrarily classified as 'active' and they were then evaluated at a range of concentrations

(between 0.1 and 100  $\mu\text{M}$ ) against the respective cell line to determine their  $\text{IC}_{50}$  values.

In the initial screening, Series-2 compounds with bioisosteric replacements showed a decreased/complete loss of activity with cell viability > 50% (See supporting information, Figure-S2). Among Series-3, the novel compounds **14f** and **16f** were found to be active against all three cell lines, and novel compounds **13f**, **15f**, **17f** and **19f** were found to be active against both the MCF-7 and MCF-7/DX cell lines. Novel compounds **12f** and **18f** were found to be active only against the MCF-7 cell line (Figure-2). These active compounds were further tested against the respective cell lines at different concentrations ranging from 0.1 to 100  $\mu\text{M}$  to determine their  $\text{IC}_{50}$  values. The determined  $\text{IC}_{50}$  values are listed in Table-2. Among these, novel compounds **15f** ( $\text{IC}_{50} = 1.0 \pm 0.1 \mu\text{M}$  and  $9.1 \pm 0.1 \mu\text{M}$  against MCF-7 and MCF-7/DX cell lines respectively) and **16f** ( $\text{IC}_{50} = 4.9 \pm 0.7 \mu\text{M}$ ,  $6.5 \pm 0.4 \mu\text{M}$  and  $8.9 \pm 0.9 \mu\text{M}$  against MCF-7, MCF-7/DX and MDA-MB-231 cell lines respectively) were identified as active compounds.



**Figure-2.** Anti-proliferative activities of compounds **12c-f** to **19c-f** against (A) MCF-7 cell line (B) MCF-7/DX cell line (C) MDA-MB-231 cell line. Cell viability was determined using MTT assay in the presence of compounds **12c-f** to **19c-f** at 10  $\mu\text{M}$  concentration against the MCF-7 cell line and MDA-MB-231 cell lines, and 50  $\mu\text{M}$

concentration against the MCF-7/DX cell line. Data are expressed as the mean  $\pm$  standard error of the mean (SEM) ( $n = 3$ ). Cells without treatment serve as control. Statistical significance was estimated, with respect to the control, by one-way ANOVA, followed by Bonferroni's *post hoc* test ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$  and  $****p < 0.0001$ ). Dashed line corresponds to 50% cell viability and those compounds showing < 50% cell viability were considered as active. Colour coding: blue-hydroxy flavone (-OH, 4-C=O), red-hydroxy 4-thioflavone (-OH, 4-C=S), purple-methoxy flavone (-OMe, 4-C=O) and green-methoxy 4-thioflavone (-OMe, 4-C=S).

**Novel insights into structure-activity relationships (SARs):** Comparison of the anti-proliferative activities of methoxy flavones (both 4-C=O and 4-C=S) with their corresponding hydroxy flavones illustrates that the methoxy flavones were less anti-proliferative than their hydroxy analogues with the exception of compound **3e** [7,8,3',4'-tetramethoxy 4-thioflavone,  $\text{IC}_{50} = 11.8 \pm 1.79 \mu\text{M}$  against the MCF-7 cell line]. For example, hydroxy flavone **4d** possesses an  $\text{IC}_{50}$  value of  $21.6 \pm 0.8 \mu\text{M}$ , whereas the  $\text{IC}_{50}$  value of its methoxy flavone derivative **4c** was found to be  $>250 \mu\text{M}$ . This highlights that the free hydroxyls are important for anti-proliferative activities (for the hydrogen bonding interactions with the potential biological cellular target).

**Table 2.**  $\text{IC}_{50}$  values of the compounds **12f** to **19f** against the MCF-7, MCF-7/DX and MDA-MB-231 cell lines and their correlation with theoretical Log P values.

| Compound   | Chemical structure | Log P       | $\text{IC}_{50}$ in MCF-7                   | $\text{IC}_{50}$ in MCF-7/DX                 | $\text{IC}_{50}$ in MDA-MB-231              |
|------------|--------------------|-------------|---|--|---|
| 18f        |                    | 2.87        | $25.9 \pm 1.6 \mu\text{M}$                  | $> 50 \mu\text{M}$                           | $> 10 \mu\text{M}$                          |
| 12f        |                    | 3.00        | $8.0 \pm 0.1 \mu\text{M}$                   | $> 50 \mu\text{M}$                           | $> 10 \mu\text{M}$                          |
| 14f        |                    | 3.40        | $7.9 \pm 2.4 \mu\text{M}$                   | $34.0 \pm 4.6 \mu\text{M}$                   | $10.9 \pm 2.4 \mu\text{M}$                  |
| <b>16f</b> |                    | <b>3.67</b> | <b><math>4.9 \pm 0.7 \mu\text{M}</math></b> | <b><math>6.50 \pm 0.4 \mu\text{M}</math></b> | <b><math>8.9 \pm 0.8 \mu\text{M}</math></b> |
| 19f        |                    | 2.87        | $8.9 \pm 0.6 \mu\text{M}$                   | $27.3 \pm 1.8 \mu\text{M}$                   | $> 10 \mu\text{M}$                          |
| 13f        |                    | 3.00        | $5.9 \pm 0.7 \mu\text{M}$                   | $41.3 \pm 1.5 \mu\text{M}$                   | $> 10 \mu\text{M}$                          |
| <b>15f</b> |                    | <b>3.40</b> | <b><math>1.0 \pm 0.1 \mu\text{M}</math></b> | <b><math>9.1 \pm 0.8 \mu\text{M}</math></b>  | $> 10 \mu\text{M}$                          |
| 17f        |                    | 3.67        | $2.5 \pm 0.1 \mu\text{M}$                   | $15.4 \pm 0.8 \mu\text{M}$                   | $> 10 \mu\text{M}$                          |

Note: Most active compounds of the series are highlighted in bold. Data represented is mean  $\pm$  SEM,  $n=3$ . Log P values were determined using ChemDraw ultra 12.1 software.

The importance of free hydroxyls for anti-proliferative activity has previously been debated in the literature, with contradicting results. Thus, the results from our

programme support findings<sup>38,39</sup> that indicate that polymethoxylation decreases the anti-proliferative activity, but contradict earlier findings that suggested higher anti-proliferative activities for polymethoxylated flavones against MCF-7<sup>20,40</sup>, human leukemic HL-60<sup>41</sup> and melanoma cell lines<sup>19</sup>.


Further, from the comparison of anti-proliferative activities between the hydroxy flavones (free -OH and 4-C=O) and their 4-thio analogues (free -OH and 4-C=S), it was apparent that the substitution of 4-C=S for 4-C=O enhances the anti-proliferative activity [compound-**2f** (free -OH and 4-C=S),  $IC_{50} = 7.9 \pm 0.8 \mu M$  < compound-**2d** (free -OH and 4-C=O),  $IC_{50} = 25.6 \pm 1.2 \mu M$ ].

**Influence of number and position of hydroxyls:** By comparing the anti-proliferative activities of flavone derivatives (free -OH and 4-C=O) with different numbers of hydroxy groups, it was observed that the anti-proliferative activities against the MCF-7 cell line were in the order pentahydroxy flavone (**5d**) [ $IC_{50} = 13.7 \pm 0.6 \mu M$ ] > tetrahydroxy flavone (**4d**) [ $IC_{50} = 21.6 \pm 0.8 \mu M$ ]  $\approx$  dihydroxy flavone (**2d**) [ $IC_{50} = 25.6 \pm 0.6 \mu M$ ]. However, an opposite correlation was observed in the case of the hydroxy 4-thioflavone derivatives (free -OH and 4-C=S), where the order of anti-proliferative activities was found to be dihydroxy 4-thioflavone (**2f**) [ $IC_{50} = 7.9 \pm 0.3 \mu M$ ] > tetrahydroxy 4-thioflavone (**4f**) [ $IC_{50} = 27.3 \pm 1.5 \mu M$ ]  $\approx$  pentahydroxy 4-thioflavone (**5f**) [ $IC_{50} = 102.6 \pm 5.4 \mu M$ ]. This indicates that the number of hydroxyls is not a determining factor for the anti-proliferative activities, in the case of hydroxy flavones (free -OH and 4-C=O). In complete contrast, the number of hydroxyl groups in hydroxy 4-thioflavones plays an important role in their anti-proliferative activities and the dihydroxy 4-thioflavones were found to be the most active flavones.

In terms of the position of the hydroxyls, flavones with 5,7-hydroxyls on the A-ring were more active than their corresponding 7,8-hydroxy flavones. For example, 5,7,3',4'-tetrahydroxy flavone (**4d**) [ $IC_{50} = 21.6 \pm 0.8 \mu M$ ] > 7,8,3',4'-tetrahydroxy flavone (**3d**) [ $IC_{50} = 97.5 \pm 6.7 \mu M$ ] and 5,7-dihydroxy 4-thioflavone (**2f**) [ $IC_{50} = 7.9 \pm 0.2 \mu M$ ] > 7,8-dihydroxy 4-thioflavone (**2e**) [ $IC_{50} = 14.7 \pm 1.0 \mu M$ ].

**Effect of bioisosteric replacements:** Replacement of the B-ring phenyl group with a bioisostere (eg either a five-membered 2-thienyl, a 2-furanyl group, or a six-membered 3-pyridyl group) resulted in a significant loss of anti-proliferative activity. This highlighted that the presence of a phenyl group as ring-B is favourable for anti-proliferative activity.

**Influence of electron-withdrawing groups:** Interestingly, introduction of EWGs at the C4' position of the phenyl group, mainly with halogens such as F (**12f** and **13f**), Cl (**14f** and **15f**) and Br (**16f** and **17f**) was found to enhance anti-proliferative activities in comparison to the flavones with an unsubstituted phenyl B-ring (compounds **1f** and **2f**). In particular, the introduction of Cl and Br groups increased the anti-proliferative potencies 2-7 fold (**14f**, **15f**, **16f** and **17f**) against MCF-7 and MCF-7/DX cell lines, and also their introduction afforded 7,8-dihydroxy 4-thioflavones with an increased anti-proliferative activity towards MDA-MB-231 cells (compound-**1f**: cell viability at 10  $\mu M$  was 79%, whereas, compound-**14f** (containing -Cl) and compound-**16f** (containing -Br) showed 49% and 20% cell viability at 10  $\mu M$  against MDA-MB-231). The pronounced activity observed for the -F, -Cl and -Br substituted 4-thioflavones could be attributed to their increased lipophilicity, as can be observed by the decrease in  $IC_{50}$  values (more active) for increasing theoretical Log P values (Table-2). A summary of SARs for the anti-proliferative activities of flavones analysed herein is depicted in Figure-3.



**Figure-3.** Summary of the SARs for the anti-proliferative activities of flavones analysed herein.

**Molecular mechanism of action:** Next, the probable molecular mechanism of the anti-proliferative activities of the flavonoids was explored. Two plausible molecular mechanisms were postulated. (a) As the majority of flavones evaluated herein exhibited a

strong and selective anti-proliferative activity against the estrogen-responsive breast cancer cell line that expresses high levels of estrogen receptor- $\alpha$  (ER $\alpha$ )<sup>42</sup>, it was anticipated that these compounds may act as estrogen-receptor antagonists by interacting with ER $\alpha$ . (b) As these compounds have been reported to interact with cell signalling proteins<sup>43,44</sup> it was hypothesised that these compounds could modulate the cell signalling proteins that are involved in cell survival and cell death.

**a) Interaction with ER $\alpha$ :** The interaction of flavones **1c-19f** with the estrogen receptor- $\alpha$  (ER $\alpha$ ) was first investigated using a molecular docking approach. For this, compounds **1c-19f** were docked sequentially into the binding site of the prepared X-ray crystallographic structure of human ER $\alpha$  complexed with an antagonist 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol [native ligand] (PDB code 1UOM, 2.28 Å resolution)<sup>45</sup> using a validated docking procedure (See experimental section). In general no correlation was observed between the order of anti-proliferative activity and their binding affinities with ER $\alpha$  (as determined by their respective docking scores). One notable exception was compound-**3e** which showed higher binding affinity towards the ER $\alpha$  receptor [(docking score of 10.02, versus the native ligand docking score of 13.0), see supporting information (Figure-S3) for details]. This indicates that the majority of the flavonoid derivatives mediate their anti-proliferative effects via estrogen-independent mechanisms. A similar observation has been reported for 5-aminoflavones, which showed remarkable anti-proliferative activity against the ER+ve MCF-7 cell line without ER competition, as determined by the ER binding assay<sup>46</sup>.

To confirm this finding, an ER $\alpha$  antagonism assay was carried out using the human estrogen receptor alpha assay kit which consists of ER $\alpha$  reporter cells in which an ER $\alpha$ -responsive promoter is functionally linked to the luciferase reporter gene, and allows quantification of changes in the ER $\alpha$  activity *via* measurement of the changes in luciferase expression. In order to evaluate whether the flavone derivatives mediate their anti-

proliferative effects *via* antagonism of ER $\alpha$ , compound-**15f** (IC<sub>50</sub> = 1  $\mu$ M) compound-**16f** (IC<sub>50</sub> = 4.9  $\mu$ M) and compound-**3e** (IC<sub>50</sub> = 11.8  $\pm$  1.79  $\mu$ M), that were potent against MCF-7 cells, were assessed for their antagonist activity at four-point concentrations (10  $\mu$ M - 0.1  $\mu$ M) in the presence of a constant concentration of 17 $\beta$ -estradiol (3.2 nM, EC<sub>75</sub>). The known antagonist fulvestrant was used as a positive control. Compounds **15f** and **16f** did not show any decrease in the luciferase activity (induced by 17 $\beta$ -estradiol), which was in contrast to fulvestrant. However, compound-**3e** showed a dose-dependent decrease in the luciferase activity [see supporting information (Figure-S4) for details]. These results support the findings from the *in silico* study that the majority of these compounds (except compound-**3e**) most likely act through an estrogen-independent mechanism.

**b) Interactions with cell signalling proteins:** Next, the signals mediated by compounds **15f** and **16f** in ER+ve MCF-7 and MCF-7/DX cells and ER-ve MDA-MB-231 cells were examined using the PathScan<sup>®</sup> Intracellular Signalling Array Kit, which allows simultaneous detection of 18 significant and well-characterised signalling molecules that undergo covalent post-translational modifications, such as phosphorylation and proteolysis (cleavage). Protein samples obtained from the treatment of MCF-7, MCF-7/DX and MDA-MB-231 cells with compounds **15f** (IC<sub>50</sub> < 10  $\mu$ M against MCF-7 and MCF-7/DX) and **16f** (IC<sub>50</sub> < 10  $\mu$ M against MCF-7, MCF-7/DX and MDA-MB-231 cells) were analysed (Figure-4). The results showed that the anti-proliferative effects were mediated by significant inhibition of the Akt associated downstream target GSK-3 $\beta$ , which is a key signalling molecule for cell survival and proliferation. In addition, compound-**15f**, which showed greater potency towards MCF-7 cells (IC<sub>50</sub> = 1  $\mu$ M for **15f** vs IC<sub>50</sub> = 4.9  $\mu$ M for **16f**), was found to trigger cell death through PARP cleavage, which is a hallmark of the cell death pathway<sup>47</sup>. This explains the greater potency of compound-**15f** towards MCF-7 cells. It is noteworthy that no caspase-3 cleavage was observed; this suggests that the observed PARP cleavage is caspase-3 independent and the activation of





PARP cleavage in MCF-7 cells might have been executed via other caspases such as caspases 6/9.<sup>48</sup> In the case of MCF-7/DX cells, compound-**16f**, that has greater activity towards MCF-7/DX cells than compound-**15f**, mediated its anti-proliferative effects through a significant reduction in the phosphorylation of several cell survival proteins such as mTOR, GSK-3 $\beta$  and Stat3, along with induction of cell death through caspase-3 and PARP cleavage. However, compound-**15f** was found to elicit its anti-proliferative effects through a reduction in the phosphorylation of GSK-3 $\beta$  as well as through induction of cell death via PARP cleavage. Thus, the higher potency of compound-**16f** could be related to its ability to downregulate multiple cell survival proteins (mTOR, GSK-3 $\beta$  and Stat3) along with its ability to induce cell death via caspase-3 and PARP cleavage.

Interestingly, treatment of MDA-MB-231 cells with compound-**16f** showed a 2-fold increase in the levels of p53 compared to the control. MDA-MB-231 cells have a mutant p53 gene<sup>49,50</sup> that is more stable and oncogenic unlike the wild type p53 in MCF-7 cells<sup>51</sup>. The presence of mutant p53 drives the invasiveness of the tumour<sup>52,53</sup>. However, the increase in the Serine-15 phosphorylated p53 (mutant) in compound-**16f** treated MDA-MB-231 cells [than the control (untreated)] linked with its profound activity suggest that compound-**16f** induces Ser-15 phosphorylation of a mutant p53 in MDA-MB-231 cells, which probably leads to the restoration of wild-type p53 DNA binding activity and induction of cell death. A similar observation has been reported for resveratrol (a chalcone) wherein cell death was induced by restoring the wild-type p53 DNA binding activity via the phosphorylation of a mutant p53 at Serine-15 in prostate cancer DU145 cells<sup>54-56</sup>. This might explain the higher activity of compound-**16f** against MDA-MB-231 cells ( $IC_{50}$  = 8.9  $\mu$ M for **16f** vs  $IC_{50}$  > 10  $\mu$ M for **15f**).

Overall, these results correlate well with the *in vitro* findings, and suggest that for the MCF-7 and MCF-7/DX cell lines, the anti-proliferative effects are mediated via ER-independent cleavage of PARP and downregulation of GSK-3 $\beta$ . For the MDA-MB-231 cell line, activity could

be due to restoration of the wild-type p53 DNA binding activity of the mutant p53 tumour suppressor gene.






**Figure-4.** Chemiluminescent array images of the PathScan Intracellular Signalling array kit revealing various phosphorylated/cleaved signalling nodes in (A) MCF-7 cells, (B) MCF-7/DX cells and (C) MDA-MB-231 cells after the treatment with compounds **15f** and **16f** at 10  $\mu$ M for 24h. Cells without treatment serve as control. Bar chart representing the fold change in the integrated density of phosphorylated/cleaved signalling nodes in the array image of (A1) MCF-7 cells, (B1) MCF-7/DX cells and (C1) MDA-MB-231 cells after the treatment with and without compounds **15f** and **16f** at 10  $\mu$ M for 24 h. Data are expressed as the mean  $\pm$  standard error of the mean (SEM) ( $n = 4$ ). Statistical significance was estimated with respect to the control by one-way ANOVA, followed by Bonferroni's post hoc test (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ). (D) Molecular mechanism of action of **15f** and **16f** in MCF-7, MCF-7/DX and MDA-MB-231 cell lines.

**Apoptosis determination:** As compounds **15f** and **16f** were found to act via induction of the apoptotic signalling pathway (PARP, caspase-3 and p53), these compounds were further assessed for their ability to induce apoptosis. For this, MCF-7 and MDA-MB-231 cells were treated (at their  $IC_{50}$  concentration for 24 h) with compounds **15f** (1  $\mu$ M and 10  $\mu$ M against MCF-7 and MDA-MB-231, respectively) or **16f** (5  $\mu$ M and 9  $\mu$ M against MCF-7 and MDA-MB-231, respectively) and

were analysed for phosphatidylserine externalization (apoptosis marker)<sup>57,58</sup> using an annexin V-FITC/propidium iodide (PI) apoptosis detection assay and flow cytometry. As shown in Figure-5, a significant increase in the percentage of apoptotic cells in comparison to the untreated control was observed in the MCF-7 cells treated with either **15f** or **16f**, and in the MDA-MB-231 cells treated with **16f**. These results clearly indicate that the flavones **15f** and **16f** potentially induce apoptosis in the MCF-7 and MDA-MB-231 cells, whilst only **16f** potentially induces apoptosis in MDA-MB-231 cells. These observations are in line with the cytotoxicity data/protein array data. Therefore, from the molecular mechanism of action studies, and the apoptotic assay, for compounds **15f** and **16f** it can be concluded that these compounds induce apoptotic cell death via PARP cleavage in MCF-7 cells, and **16f** triggers apoptosis by p53 induction in the MDA-MB-231 cell line.




**Figure-5.** Apoptosis detection in MCF-7 and MDA-MB-231 cells by flow cytometry. MCF-7 cells were treated with compounds **15f** and **16f** at 1  $\mu$ M and 5  $\mu$ M respectively for 24 h and MDA-MB-231 cells were treated with compounds **15f** and **16f** at 10  $\mu$ M and 9  $\mu$ M respectively for 24 h. The quadrants were set based on the population of healthy, unstained cells in untreated samples (control) compared to cells treated with 5  $\mu$ M camptothecin for 24 h. **A**- Representative figures showing population of unstained live (annexin V- PI-, lower left), apoptotic (annexin V+ PI-, lower right), dead (annexin V+ PI+, upper right) and necrotic (annexin V- PI+, upper left) cells. **B**- Bar chart represent the quantification of the apoptotic cells induced upon the treatment of MCF-7 and MDA-MB-

231 cells with compounds **15f** and **16f**. Data are expressed as mean  $\pm$  standard error of the mean (SEM),  $n = 3$ . Statistical significance was estimated with respect to the control (untreated sample) by one-way ANOVA, followed by Bonferroni's *post hoc* test ( $n$  = nonsignificant; \*,  $p < 0.05$ , \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ , \*\*\*\*,  $p < 0.0001$ ).

**NCI 60 cell line screening:** Finally, to further probe the promising and significant anti-proliferative activities of the novel flavonoids **15f** and **16f**, they were screened for *in vitro* cytotoxicity by the National Cancer Institute Developmental Therapeutic Program<sup>59</sup>, USA (NCI/DTP, USA). Initial evaluation was performed at a single dose of 10  $\mu$ M against 60 different human tumour cell lines using the Sulforhodamine B cytotoxic assay.<sup>60</sup> Both compounds showed potential growth inhibition against a wide range of cancer cell lines (See Supporting information Information). As a result, they were selected for further 5-dose assay screening against the 60 cell lines (0.01  $\mu$ M - 100  $\mu$ M). Three end points, specifically the  $GI_{50}$  (concentration that causes 50% growth inhibition), TGI (total growth inhibition) and  $LC_{50}$  (the concentration of the drug at which the original cell number is reduced by 50%) were determined. The mean inhibitory doses (MID) against 60 cell lines for compound-**15f** and compound-**16f** were 2.81  $\mu$ M and 2.39  $\mu$ M respectively. The  $GI_{50}$  values determined for these two compounds against 60 cell lines are presented in Table-3. Interestingly, both compounds **15f** and **16f** exhibited nanomolar range activity various cell lines. Specifically, compound-**15f** showed the highest cytotoxicity against the breast cancer cell lines MCF-7 ( $GI_{50} = 0.18 \mu$ M), T-47D ( $GI_{50} = 0.03 \mu$ M) and MDA-MB-468 ( $GI_{50} = 0.47 \mu$ M), HCT-15 (colon cancer,  $GI_{50} = 0.48 \mu$ M), OVCAR-4 (ovarian,  $GI_{50} = 0.57 \mu$ M). Also, compound-**16f**, showed significant cytotoxicity against NCI-H460 (NSCLC,  $GI_{50} = 0.97 \mu$ M) and HCT-15 (colon cancer,  $GI_{50} = 0.85 \mu$ M). The cytotoxicity profile of the well-known flavone chrysin (**2d**) [NSC407436] was retrieved from the NCI database (mean dose graph provided in supporting information) for comparison. Overall, compounds-**15f** and **16f** were found to be 7-8 fold more potent than chrysin (MID-20.10  $\mu$ M, against 51 cell lines). In particular, compounds-**15f** and **16f** were found to be 46 fold and 13 fold more active than chrysin against an ovarian

OVCAR-4 cell line, 43 fold and 24 fold more active than chrysin against colon HCT-15 and 5 fold and 15 fold more active than chrysin against the NSCLC NCI-H460 cell line, respectively (Figure-6).



**Figure-6.** Comparison of  $GI_{50}$  values of compounds **15f** and **16f** with **2d** (chrysin, a well-known natural flavone). Data for **2d** (chrysin) were obtained from NCI/DTP screening: December 2010 (NSC407436).

**Table 3.**  $GI_{50}$  values for 15f and 16f against 60 cell lines obtained from NCI/DTP screening

| Panel/Cell line                   | $GI_{50}$ ( $\mu$ M) |             |
|-----------------------------------|----------------------|-------------|
|                                   | 15f                  | 16f         |
| <b>Leukaemia</b>                  |                      |             |
| CCRF-CEM                          | 4.13                 | 2.53        |
| HL-60                             | 2.99                 | 1.66        |
| K-562                             | 3.39                 | 2.47        |
| MOLT-4                            | 3.93                 | 2.16        |
| RPMI-8226                         | 2.95                 | 1.32        |
| SR                                | 3.97                 | 2.54        |
| <b>Non-Small Cell Lung Cancer</b> |                      |             |
| A549/ATCC                         | 9.20                 | 3.26        |
| EKVX                              | 17.3                 | 17.9        |
| HOP-62                            | 1.95                 | 1.50        |
| HOP-92                            | 1.76                 | 1.69        |
| NCI-H226                          | 14.6                 | 7.22        |
| NCI-H23                           | 1.95                 | 1.52        |
| NCI-H322M                         | 2.23                 | 1.89        |
| <b>NCI-H460</b>                   | <b>3.09</b>          | <b>0.97</b> |
| NCI-H522                          | 2.57                 | 1.16        |
| <b>Colon Cancer</b>               |                      |             |
| COLO 205                          | 16.8                 | 10.7        |
| HCC-2998                          | 1.74                 | 2.28        |
| HCT-116                           | 2.78                 | 2.22        |
| <b>HCT-15</b>                     | <b>0.48</b>          | <b>0.85</b> |
| HT29                              | 19.4                 | 4.56        |
| KM12                              | 2.17                 | 3.35        |
| SW-620                            | 3.85                 | 2.60        |
| <b>CNS Cancer</b>                 |                      |             |
| SF-268                            | 3.57                 | 2.18        |
| SF-295                            | 8.97                 | 4.01        |
| SF-539                            | 3.48                 | 1.98        |
| SNB-19                            | 3.85                 | 2.95        |
| SNB-75                            | 2.91                 | 4.55        |

|                        |             |             |
|------------------------|-------------|-------------|
| U251                   | 3.36        | 2.44        |
| <b>Melanoma</b>        |             |             |
| LOX IMVI               | 3.17        | 1.18        |
| MALME-3M               | 1.81        | 1.87        |
| M14                    | 3.25        | 2.01        |
| MDA-MB-435             | 3.46        | 2.98        |
| SK-MEL-2               | 2.69        | 2.27        |
| SK-MEL-28              | 4.67        | 2.94        |
| SK-MEL-5               | 2.05        | 1.79        |
| UACC-257               | 2.93        | 2.88        |
| UACC-62                | 3.27        | 2.09        |
| <b>Ovarian Cancer</b>  |             |             |
| IGROV1                 | 1.14        | 2.56        |
| OVCAR-3                | 1.96        | 1.23        |
| <b>OVCAR-4</b>         | <b>0.57</b> | <b>2.03</b> |
| OVCAR-5                | 12.1        | 5.83        |
| OVCAR-8                | 3.34        | 2.28        |
| NCI/ADR-RES            | 2.82        | 1.43        |
| SK-OV-3                | 3.61        | 2.60        |
| <b>Renal Cancer</b>    |             |             |
| 786-0                  | 7.35        | 2.89        |
| A498                   | 1.22        | 2.15        |
| ACHN                   | 2.53        | 2.35        |
| CAKI-1                 | 3.12        | 2.65        |
| RXF393                 | 4.22        | 2.51        |
| SN12C                  | 2.83        | 2.61        |
| TK-10                  | 4.60        | 4.16        |
| UO-31                  | 1.28        | 1.02        |
| <b>Prostate Cancer</b> |             |             |
| PC-3                   | 3.21        | 2.92        |
| DU-145                 | 4.26        | 2.67        |
| <b>Breast Cancer</b>   |             |             |
| <b>MCF-7</b>           | <b>0.18</b> | <b>1.46</b> |
| MDA-MB-231/ATCC        | 2.20        | 1.81        |
| HS 578T                | 5.26        | 6.69        |
| BT-549                 | 3.40        | 2.19        |
| <b>T-47D</b>           | <b>0.03</b> | <b>1.27</b> |
| <b>MDA-MB-468</b>      | <b>0.47</b> | <b>2.08</b> |

Note: Sub-micromolar range GI<sub>50</sub> values are highlighted in bold.

## Conclusions

A library of 76 compounds containing structurally related methoxy and hydroxy flavones, and their 4-thio analogues, has been designed, synthesised and evaluated for anti-proliferative activity against the breast cancer cell lines MCF-7 (ER+ve), MCF-7/DX (ER+ve, anthracycline resistant) and MDA-MB-231 (ER-ve). Within this library, 42 compounds were prepared and characterised for the first time within our laboratory. The study provided significant insight into the structural features required for enhancing the anti-proliferative profiles of flavones, and identified two novel hydroxy 4-thioflavones **15f** and **16f**, as lead anti-proliferative agents (**15f** (IC<sub>50</sub> = 1.0 ± 0.1 μM and 9. ±

0.1 μM against MCF-7 and MCF-7/DX cell lines, respectively) and **16f** (IC<sub>50</sub> = 4.9 ± 0.7 μM, 6.5 ± 0.4 μM and 8.9 ± 0.8 μM against MCF-7, MCF-7/DX and MDA-MB-231 cell lines, respectively)). A systematic SAR study highlighted the presence of free hydroxyl groups, and the B-ring phenyl groups, as essential for enhanced anti-proliferative activities. Replacement of the 4-C=O functional group with the 4-C=S functional group also enhanced the anti-proliferative activities. Incorporation of lipophilic electron withdrawing groups at C4' of the B-ring phenyl was found to be favourable, and the increased lipophilicity correlates well with the greater anti-proliferative activities. Molecular mechanistic studies have suggested that the anti-proliferative effects of flavones **15f** and **16f** are mediated via ER-independent cleavage of PARP and downregulation of GSK-3β in the case of MCF-7 and MCF-7/DX cell lines. For the MDA-MB-231 cell line, a probable restoration of the wild-type p53 DNA binding activity of mutant p53 tumour suppressor gene was indicated. Taken together, these results demonstrate that the novel thioflavones **15f** and **16f** offer considerable potential as anti-proliferative agents within medicinal chemistry programmes focussed on cancer. In addition, the SARs derived herein are likely to contribute significantly to the design and synthesis of novel thioflavones for further therapeutic applications.

## Experimental

### Materials and methods

**Cell line and culture:** MCF-7 (ER +ve breast cancer cell line) was provided by Tenovus Centre for Cancer Research (Cardiff, UK), MCF-7/DX (a doxorubicin resistant phenotype of MCF-7) was obtained as a gift from Professor Luigi Quintieri from the University of Padova, Italy and MDA-MB-231 (ER -ve breast cancer cell line) were purchased as a frozen stock from the European Collection of Cell Cultures (ECACC). MCF-7 and MCF-7/DX cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum, MDA-MB-231 cells were cultured in DMEM supplemented with 10% fetal bovine serum. All of the cell culture reagents were obtained from Lonza, UK. The PathScan

Intracellular Signalling array kit was purchased from Cell Signaling (Catalog number-7323). ER $\alpha$  receptor antagonist kit was purchased from Indigo biosciences, USA. Annexin V/propidium iodide apoptosis detection kit I was procured from BD, Pharmingen™, UK. For the cell culture experiments, the stock solutions of the test compounds (10 mg/mL) were prepared in sterile DMSO and ethanol (1:1 v/v) and these stocks were then appropriately diluted with the complete culture medium and, the ethanol and DMSO levels were maintained below 1% in the test concentrations. The IC<sub>50</sub> values were calculated using MS excel 2010. Molecular docking was performed using SYBYL-X-2.1 software.

**Synthesis:** See the supporting information.

**Anti-proliferative assay:** Anti-proliferative activities of the compounds were assessed using the MTT assay at 72 h of treatment. For this, MCF-7 and MCF-7/DX cells were seeded at a density of  $4 \times 10^4$  cells/mL and MDA-MB-231 cells were seeded at a density of  $2 \times 10^4$  cells/mL into 96 well plates and incubated for 24 h to allow attachment. After 24 h, the cells were treated with these synthesised derivatives at a range of concentrations (0 to 250  $\mu$ M) or at single doses (10  $\mu$ M against MCF-7 and MDA-MB-231 cells, and 50  $\mu$ M against MCF-7/DX cells) for 67 h. After 67 h, MTT assay<sup>61</sup> was carried out by the addition of 20  $\mu$ L of MTT (5mg/mL) solution in PBS into each well and the cells were incubated for 5 h. The purple crystals formed were dissolved in 100  $\mu$ L of DMSO and the plates were read at 570 nm using a SPECTRA max UV spectrometer (Bio-Rad). The data represented are the mean of the three individual experiments. The cell viability of the control is considered to be 100%.

IC<sub>50</sub> values presented here correspond to the concentration  $(T/C) \times 100 = 50$ , where T = Absorbance of the test well after 72 h exposure to the test compound, C = Absorbance of control well after 72 h.

GI<sub>50</sub> values presented here involve a correction for the cell count at time zero. Therefore the GI<sub>50</sub> value for a test drug corresponds to the concentration  $[(T - T_0)/(C - T_0)] \times 100 = 50$ , where T = Absorbance of the test well

after 48 h exposure to the test compound, C = Absorbance of control after 48 h and T<sub>0</sub> = Absorbance at time zero.

### Molecular docking

**Docking validation:** To validate the accuracy of the docking procedure to be used, the original ligands were extracted from the coordinate files (taken from the Protein Data Bank PDB), and then docked again into the corresponding crystal structure of the proteins, using the automated docking procedure in the program Surflex-Dock (SFXC)<sup>62,63</sup>, as provided by SYBYL-X-2.1. The resulting ligand conformation from the docking procedure was compared with the ligand conformation as found in the actual crystal structure of the complex. Comparative structural orientation of the ligand was calculated as the root mean square deviation (RSMD) between the docked ligand and the ligand as found in the crystal structure, using the programme LSQKAB, as provided in the CCP4<sup>64</sup> suite. If the root mean square deviation (RMSD) value between the real and the best-scored conformations is equal to or less than 2.0 Å (representing the grid spacing used for the docking procedure), then the docking process was considered successful<sup>65</sup>. In this case the docking procedure was first validated by re-docking the extracted co-crystallised ligand of human estrogen receptor- $\alpha$  (ER $\alpha$ ) (2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol) into the prepared target protein to be used for docking. The RMSD between the docked conformation, as generated by the docking algorithm and the native co-crystallised ligand conformation was found to be 0.12 Å, which was well within the 2 Å grid spacing used in the docking procedure, indicating that the docking method to be used was reliable and valid. Furthermore, the interactions between the docked ligand and the prepared target receptor mimicked those observed in the crystal structure of the same.

**Docking procedure:** Docking studies were performed using the programme Surflex-Dock (SFXC)<sup>62</sup> as provided by Sybyl-X 2.1. The X-ray crystallographic structures of human estrogen receptor- $\alpha$  (ER $\alpha$ ) complexed with an antagonist 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-

phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol (PDB code-1UOM, 2.28 Å resolution)<sup>45</sup> was retrieved from the Protein Data Bank. The protein structure was prepared for docking using the Biopolymer Structure Preparation Tool with the implemented default settings provided in the SYBYL programme suite. Hydrogens were added to the protein structures in idealised geometries and an overall energy minimisation of each protein was performed using the MMFF94 force field, employing a conjugate gradient algorithm<sup>66</sup> with a convergence criterion of 0.5 kcal/mol Å<sup>-1</sup> and up to 5000 iterations. Finally, before the docking run, all water molecules were removed and the ligand 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol was extracted from the coordinate file of the ER α (PDB-1UOM). The protomol, representing the ligand binding groove, was generated using a ligand directed method, which allows the docking of ligands into predefined sites, as defined by occupancy of any co-crystallised ligand at the site of interest.

The Surflex-X docking algorithm docks a given ligand to a receptor using a flexible ligand and a semi-flexible receptor; in this case the peptides were allowed to be fully flexible while the receptor was semi-flexible. This approach allows for optimisation of potentially favourable molecular interactions, such as those defined by hydrogen bond and van der Waal forces. The docking results yield a docking score, which takes into consideration entropic, polar, hydrophobic, repulsive and desolvation factors. Here, the docking scores were expressed in  $-\log_{10}(K_d)$  units to represent binding affinities, where  $K_d$  is the dissociation constant. The free energy of binding of the ligand to the protein was extrapolated from equation (1).

$$\text{Free energy of binding} = RT \log_e K_d \dots (1)$$

The docking results were visualised using the programme PyMOL<sup>67,68</sup> and the molecular interactions of the docked ligands were analysed by the programme CONTACTS, as provided in the CCP4 suite of programmes<sup>64,69,70</sup>. Potential hydrogen bonds were assigned if the distance between two electronegative atoms was less than 3.3 Å, whereas any separation

greater than 3.3 Å, but less than 4.5 Å, was considered a van der Waal interaction.

**ERα antagonist assay:** ERα reporter cells consisting of an ERα-responsive promoter gene functionally linked to the luciferase gene were defrosted and seeded into a 96-well plate and these cells were immediately dosed with the test compounds at different concentrations (10-0.1 μM) and with 17β estradiol (3.2 nM, EC<sub>75</sub> concentration) according to the manufacturer's protocol. After 24 h incubation in the presence of the test compound or solvent (DMSO), the cell viability of these treated/untreated reporter cells was measured to eliminate false positives using the fluorescence-based live cell multiplex (LCM) assay. The fluorescence from the live cells was measured using the plate reader with the filter combination of [485nmEx | 535nmEm]. Following this, fold reduction in the luciferase intensity, which is the measure of the antagonist activity was measured by using a luminometer (TECAN) according to the manufacturer's protocol. The data are expressed as the fold reduction as compared to the control. The mean of three experiments and the standard error is reported.

**PathScan sandwich immunoassay:** The PathScan Intracellular Signalling array kit was used for the simultaneous detection of 18 significant and well-characterised cellular proteins and signalling nodes that were phosphorylated or cleaved at the specific residues.

**Preparation of cell lysate:** MCF-7 and MCF-7/DX cells (8 x 10<sup>4</sup> cell/mL) and MDA-MB-231 cells (4 x 10<sup>4</sup> cells/mL) were seeded into 24 well plates (2 mL/well) and incubated for 24 h. After 24 h, the cells were treated with the test compounds at 10 μM concentration for 24 h. Following this 24 h exposure, the cells were washed with ice-cold 1X phosphate-buffered saline and lysed in 1X cell lysis buffer provided (phosphatase and protease inhibitors added). These lysates were quantified using the BCA protein assay.

**Assay procedure:** The array blocking buffer was added to each well of the glass slide provided and incubated

for 15 min at room temperature. Subsequently, the cell lysate, diluted to 0.3 mg/mL in array diluents, was added to each well and incubated for 2 h at room temperature. Subsequent to washing, the detection antibody cocktail was added to each well and incubated for 1 h at room temperature. Horseradish peroxidase (HRP)-linked streptavidin was added to each well and incubated for 30 min at room temperature. The slide was then covered with LumiGLO/Peroxide reagent (Cell Signaling Technology) and exposed to film for 2–30 sec. The image was captured by a digital imaging system, ImageQuant LAS 4000 (GE Healthcare).

**Apoptosis detection assay:** Apoptosis in MCF-7 and MDA-MB-231 cells was assayed by annexin V and propidium iodide (PI) co-staining using an Annexin-V-FITC staining kit according to the manufacturer's instruction.  $1 \times 10^6$  MCF-7 and MDA-MB-231 cells were plated into a 6 well plate ( $3.4 \times 10^5$  cells/mL, 3 mL/well). After 24 h incubation, cells were treated without and with test compounds (at their  $IC_{50}$  concentration) for 24 h. Cells were harvested using Accutase™ Cell Detachment Solution (1 mL/well) for 5 min at 37 °C. Accutase was inactivated by addition of complete medium (2 mL). Cells were collected by centrifugation at 100 x g and the pellet was washed twice with cold PBS and then resuspended in 1 mL of annexin-binding buffer. 100 µL of the cell suspension was transferred to 1.5 mL eppendorf tube and 5 µL of FITC-conjugated annexin V and 5 µL of PI was added and incubated in dark for 15 min at room temperature. After 15 min incubation 400 µL of annexin binding buffer was added to the cells and the fluorescence was measured using BD accuri™ instrument flow cytometry. The instrument was set for FL1 (annexin V-FITC) vs FL3 (PI) bivariate analysis. Data from 10,000 cells/sample was collected and dot plots of FL1 vs FL3 were generated. The quadrants were set based on the population of healthy, unstained cells in untreated samples compared to cells treated with a known apoptotic inducer camptothecin (5 µM) for 24 h. BD CSampler™ software was used to calculate the percentage of the cells in the respective quadrants. The experiment was performed in triplicate.

## Acknowledgements

Financial support to DR from the Felix trust is gratefully acknowledged. We thank Amit Kumar Rajora for his help with the sample preparation for microarray experiments. We also thank the University of Reading for the provision of the Chemical Analysis Facility and Dr Philip Dash, University of Reading, UK for providing MDA-MB-231 cells. We gratefully acknowledge NCI, USA for accepting and screening our compounds against 60 cell lines [NSC reference numbers- 783090 (**15f**) and 783091 (**16f**)].

## Abbreviations

DMSO-Dimethylsulfoxide, DCM-Dichloromethane, EtOAc-Ethylacetate, MTT-3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, NMR-Nuclear magnetic resonance, IR-Infrared; FTMS-Fourier transform mass spectroscopy, ESI-Electron spray ionisation, ERK1/2-extracellular signal-regulated kinase, mTOR-mammalian target of rapamycin, PARP-Poly (ADP-ribose) polymerase, AMPK $\alpha$ -5' adenosine monophosphate-activated protein kinase, p53-phosphoprotein53, GSK-3 $\beta$ - Glycogen synthase kinase-3 $\beta$ , Bad-Bcl-2-associated death promoter, PRAS40-proline-rich Akt substrate of 40 kDa, PI3K-Phosphatidylinositol-4,5-bisphosphate-3-kinase, MMFF94-Merck Molecular Force Field94.

## Notes

The authors declare no competing financial interest.

## References

- 1 A. L. Harvey, R. Edrada-Ebel and R. J. Quinn, *Nat Rev Drug Discov*, 2015, **14**, 111–129.
- 2 L. Ouyang, Y. Luo, M. Tian, S.-Y. Zhang, R. Lu, J.-H. Wang, R. Kasimu and X. Li, *Cell Prolif.*, 2014, **47**, 506–515.
- 3 W. Ren, Z. Qiao, H. Wang, L. Zhu and L. Zhang, *Med. Res. Rev.*, 2003, **23**, 519–534.
- 4 P. Batra and A. K. Sharma, *3 Biotech*, 2013, **3**, 439–459.
- 5 J. Carini, F. Klamt and V. Linck, *RSC Adv.*, 2014, **4**, 3131–3144.
- 6 A. K. Verma and R. Pratap, *Nat. Prod. Rep.*, 2010, **27**, 1571–1593.

- 7 R. S. Keri, S. Budagumpi, R. K. Pai and R. G. Balakrishna, *Eur. J. Med. Chem.*, 2014, **78**, 340–374.
- 8 A. Gaspar, M. J. Matos, J. Garrido, E. Uriarte and F. Borges, *Chem. Rev.*, 2014, **114**, 4960–4992.
- 9 C. Kanadaswami, L. T. Lee, P. P. H. Lee, J. J. Hwang, F. C. Ke, Y. T. Huang and M. T. Lee, *In Vivo (Brooklyn)*, 2005, **19**, 895–910.
- 10 D. Ravishankar, A. K. Rajora, F. Greco and H. M. I. Osborn, *Int. J. Biochem. Cell Biol.*, 2013, **45**, 2821–31.
- 11 S. Kawaii, Y. Tomono, E. Katase, K. Ogawa and M. Yano, *Biosci. Biotechnol. Biochem.*, 1999, **63**, 896–899.
- 12 A. M. Senderowicz, *Invest. New Drugs*, 1999, **17**, 313–320.
- 13 S. Burdette-Radoux, R. G. Tozer, R. C. Lohmann, I. Quirt, D. S. Ernst, W. Walsh, N. Wainman, A. D. Colevas and E. A. Eisenhauer, *Invest. New Drugs*, 2004, **22**, 315–322.
- 14 J. A. Jones, A. S. Rupert, M. Poi, M. A. Phelps, L. Andritsos, R. Baiocchi, D. M. Benson, K. A. Blum, B. Christian, J. Flynn, S. Penza, P. Porcu, M. R. Grever and J. C. Byrd, *Am. J. Hematol.*, 2014, **89**, 19–24.
- 15 C. Loguercio and D. Festi, *World J. Gastroenterol.*, 2011, **17**, 2288–2301.
- 16 D. Ferry, A. Smith and J. Malkhandi, *Clin. Cancer Res.*, 1996, 659–668.
- 17 P. J. Mulholland, D. R. Ferry, D. Anderson, S. A. Hussain, A. M. Young, J. E. Cook, E. Hodgkin, L. W. Seymour and D. J. Kerr, *Ann. Oncol.*, 2001, **12**, 245–248.
- 18 S. KAWAII, Y. TOMONO, E. KATASE, K. OGAWA and M. YANO, *Biosci. Biotechnol. Biochem.*, 2014, **63**, 896–899.
- 19 J. Yáñez, V. Vicente, M. Alcaraz, J. Castillo, O. Benavente-García, M. Canteras and J. A. L. Teruel, *Nutr. Cancer*, 2004, **49**, 191–199.
- 20 J. A. Manthey and N. Guthrie, *J. Agric. Food Chem.*, 2002, **50**, 5837–5843.
- 21 P. Parajuli, N. Joshee, A. M. Rimando, S. Mittal and A. K. Yadav, *Planta Med.*, 2009, **75**, 41–48.
- 22 M. Lopez-Lazaro and M. Akiyama, *Curr Med Chem Anti-Canc Agents*, 2002, **2**, 691–714.
- 23 M. López-Lázaro, M. Gálvez, C. Martín-Cordero and M. J. Ayuso, *Stud. Nat. Prod. Chem.*, 2002, **27**, 891–932.
- 24 J. F. W. McOmie, M. L. Watts and D. E. West, *Tetrahedron*, 1968, **24**, 2289–2292.
- 25 W. Baker, *J. Chem. Soc.*, 1933, 1381–1389.
- 26 M. P. Cava and M. I. Levinson, *Tetrahedron*, 1985, **41**, 5061–5087.
- 27 J. A. and R. Robinso, *J. Chem. Soc.*, 1926, **129**, 2334–2336.
- 28 D. Ravishankar, K. a. Watson, S. Y. Boateng, R. J. Green, F. Greco and H. M. I. Osborn, *Eur. J. Med. Chem.*, 2015, **97**, 259–274.
- 29 I. L. Martins, C. Charneira, V. Gandin, J. L. Ferreira da Silva, G. C. Justino, J. P. Telo, A. J. S. C. Vieira, C. Marzano and A. M. M. Antunes, *J. Med. Chem.*, 2015.
- 30 J. G. Topliss, *J. Med. Chem.*, 1972, **15**, 1006–1011.
- 31 P. F. Devitt, A. Timoney and M. A. Vickars, *J. Org. Chem.*, 1961, **26**, 4941–4944.
- 32 C. Pouget, F. Lauthier, A. Simon, C. Fagnere, J. P. Basly, C. Delage and A. J. Chulia, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 3095–3097.
- 33 N. Yao, C. Y. Chen, C. Y. Wu, K. Motonishi, H. J. Kung and K. S. Lam, *J. Med. Chem.*, 2011, **54**, 4339–4349.
- 34 K. Sak, *Pharmacogn. Rev.*, 2014, **8**, 122–46.
- 35 Indap M A, R. S, M. Leena and R. KVK, *Indian J Pharm Sci*, 2006, **68**, 465–469.
- 36 S. Yadegarynia, A. Pham, A. Ng, D. Nguyen, T. Lialiutska, A. Bortolazzo, V. Sivryuk, M. Bremer and J. B. White, *Nat Prod Commun*, 2012, **7**, 1295–1304.
- 37 E. Mechetner, A. Kyshtoobayeva, S. Zonis, H. Kim, R. Stroup, R. Garcia, R. J. Parker and J. P. Fruehauf, *Clin. Cancer Res.*, 1998, **4**, 389–398.
- 38 J. B. Daskiewicz, F. Depeint, L. Viornery, C. Bayet, G. Comte-Sarrazin, G. Comte, J. M. Gee, I. T. Johnson, K. Ndjoko, K. Hostettmann and D.




## ARTICLE

## Journal Name

- Barron, *J. Med. Chem.*, 2005, **48**, 2790–2804. 55 H. Y. Lin, H. Y. Tang, F. B. Davis and P. J. Davis, *Ann. N. Y. Acad. Sci.*, 2011, **1215**, 79–88.
- 39 I. N. Sergeev, C.-T. Ho, S. Li, J. Colby and S. Dushenkov, *Mol. Nutr. Food Res.*, 2007, **51**, 1478–1484. 56 A. Shih, S. Zhang, H. J. Cao, S. Boswell, Y.-H. Wu, H.-Y. Tang, M. R. Lennartz, F. B. Davis, P. J. Davis and H.-Y. Lin, *Mol. Cancer Ther.*, 2004, **3**, 1355–1364.
- 40 T. Walle, *Int. J. Mol. Sci.*, 2009, **10**, 5002–5019. 57 M. C. Willingham, *J. Histochem. Cytochem.*, 1999, **47**, 1101–1110.
- 41 T. Hirano, M. Gotoh and K. Oka, *Life Sci.*, 1994, **55**, 1061–1069. 58 K. Emoto, N. Toyama-Sorimachi, H. Karasuyama, K. Inoue and M. Umeda, *Exp. Cell Res.*, 1997, **232**, 430–434.
- 42 M. Lacroix and G. Leclercq, *Breast Cancer Res. Treat.*, 2004, **83**, 249–289. 59 R. H. Shoemaker, *Nat. Rev. Cancer*, 2006, **6**, 813–823.
- 43 N. Sharma, M. Dobhal, Y. Joshi and M. Chahar, *Pharmacogn. Rev.*, 2011, **5**, 1. 60 V. Vichai and K. Kirtikara, *Nat. Protoc.*, 2006, **1**, 1112–1116.
- 44 S. Kumar and A. K. Pandey, *Sci. World J.*, 2013, 2013. 61 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 45 J. Renaud, S. F. Bischoff, T. Buhl, P. Floersheim, B. Fournier, C. Halleux, J. Kallen, H. Keller, J.-M. Schlaeppli and W. Stark, *J. Med. Chem.*, 2003, **46**, 2945–2957. 62 A. N. Jain, *J. Med. Chem.*, 2003, **46**, 499–511.
- 46 T. Akama, Y. Shida, T. Sugaya, H. Ishida, K. Gomi and M. Kasai, *J. Med. Chem.*, 1996, **39**, 3461–3469. 63 A. N. Jain, *J. Comput. Aided. Mol. Des.*, 2007, **21**, 281–306.
- 47 G. V. Chaitanya, A. J. Steven and P. P. Babu, *Cell Commun. Signal.*, 2010, **8**, 31. 64 *Acta Crystallogr., Sect. D Biol. Crystallogr.*, 1994, **D50**, 760–763.
- 48 L. M. Mooney, K. a Al-Sakkaf, B. L. Brown and P. R. M. Dobson, *Br. J. Cancer*, 2002, **87**, 909–917. 65 R. Wang, Y. Lu and S. Wang, *J. Med. Chem.*, 2003, **46**, 2287–2303.
- 49 M. Olivier, R. Eeles, M. Hollstein, M. A. Khan, C. C. Harris and P. Hainaut, *Hum. Mutat.*, 2002, **19**, 607–614. 66 M. J. D. Powell, *Math. Program.*, 1977, **12**, 241–254.
- 50 L. Hui, Y. Zheng, Y. Yan, J. Bargonetti and D. A. Foster, *Oncogene*, 2006, **25**, 7305–7310. 67 W. DeLano, *CCP4 Newsl. Protein Crystallogr.*, 2002.
- 51 A. L. Gartel, C. Feliciano and A. L. Tyner, *Oncol Res*, 2003, **13**, 405–408. 68 D. Seeliger and B. L. De Groot, *J. Comput. Aided. Mol. Des.*, 2010, **24**, 417–422.
- 52 M. Hsiao, J. Low, E. Dorn, D. Ku, P. Pattengale, J. Yeargin and M. Haas, *Am. J. Pathol.*, 1994, **145**, 702–714. 69 K. Cowtan, P. Emsley and K. S. Wilson, *Acta Crystallogr. Sect. D Biol. Crystallogr.*, 2011, **67**, 233–234.
- 53 P. A. J. Muller, P. T. Caswell, B. Doyle, M. P. Iwanicki, E. H. Tan, S. Karim, N. Lukashchuk, D. A. Gillespie, R. L. Ludwig, P. Gosselin, A. Cromer, J. S. Brugge, O. J. Sansom, J. C. Norman and K. H. Vousden, *Cell*, 2009, **139**, 1327–1341. 70 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. S. Wilson, *Acta Crystallogr. Sect. D Biol. Crystallogr.*, 2011, **67**, 235–242.
- 54 H.-Y. Lin, A. Shih, F. B. Davis, H.-Y. Tang, L. J. Martino, J. A. Bennett and P. J. Davis, *J. Urol.*, 2002, **168**, 748–755.

## Graphical abstract



**RSC Advances**

ARTICLE

RSC Advances Accepted Manuscript